# SLC6A12

## Overview
The SLC6A12 gene encodes the protein known as betaine/GABA transporter 1 (BGT1), which is a member of the solute carrier family 6 (SLC6). This family is characterized by its role in the transport of neurotransmitters and other solutes across cell membranes. BGT1 is a transmembrane protein that facilitates the sodium- and chloride-dependent transport of betaine and gamma-aminobutyric acid (GABA), playing a significant role in osmoregulation and neurotransmitter balance. The protein's structure includes 12 transmembrane domains, forming a LeuT-fold that is typical of SLC transporters, allowing it to undergo conformational changes necessary for substrate transport (Pramod2013SLC6; Colas2020Toward). BGT1 is primarily expressed in the kidney and liver, where it contributes to cellular adaptation to osmotic stress and liver metabolism, respectively (Zhou2012The; Kempson2014The). Although present in the brain, its expression is limited compared to other GABA transporters, suggesting a more specialized role in this organ (Kempson2014The).

## Structure
The SLC6A12 gene encodes the betaine/GABA transporter 1 (BGT1), a member of the solute carrier family 6 (SLC6) involved in neurotransmitter transport. The primary structure of BGT1 consists of amino acid sequences that form transmembrane domains, typical of the SLC6 family, which generally have 12 transmembrane domains (TMs) (Pramod2013SLC6). The secondary structure includes alpha helices, which are crucial for the protein's function and stability (Freissmuth2017SLC6).

The tertiary structure of BGT1 involves the arrangement of these helices within the membrane, forming a 5 + 5 helical architecture, where TMs 1-5 and TMs 6-10 create two antiparallel pentahelical bundles (Pramod2013SLC6). This structure is characteristic of the LeuT-fold, a common motif in SLC transporters, which facilitates substrate transport through conformational changes (Colas2020Toward).

Post-translational modifications of BGT1 may include phosphorylation, which can influence transporter activity and regulation (Pramod2013SLC6). The protein's quaternary structure may involve oligomerization, although specific details on this aspect are not provided in the context. BGT1's structure is essential for its role in transporting betaine and GABA, contributing to osmoregulation and neurotransmitter balance (Kickinger2021Molecular).

## Function
The SLC6A12 gene encodes the betaine/GABA transporter 1 (BGT1), which is a member of the solute carrier family 6. BGT1 is primarily involved in the transport of betaine and gamma-aminobutyric acid (GABA) across cell membranes in a sodium- and chloride-dependent manner. This transporter plays a crucial role in osmoregulation, particularly in the kidney medulla, where it helps cells adapt to hyperosmolar conditions by accumulating betaine, an organic osmolyte that protects cells from osmotic stress without disrupting macromolecular function (Pramod2013SLC6; Kempson2014The).

In the liver, BGT1 is highly expressed and contributes to liver metabolism by facilitating the uptake of betaine, which serves as a methyl donor in the conversion to methionine, a process catalyzed by the enzyme BHMT1 (Zhou2012The). Although BGT1 is present in the brain, its expression is significantly lower compared to other GABA transporters, suggesting a limited role in GABA uptake and brain excitability control (Kempson2014The; Lehre2011Deletion). The transporter is primarily located in the leptomeninges rather than in neurons or glia, indicating that its function in the brain may not be directly related to neurotransmitter recycling (Kempson2014The).

## Clinical Significance
The SLC6A12 gene, encoding the betaine-GABA transporter (BGT1), has been implicated in various clinical conditions due to its role in betaine and GABA transport. Alterations in SLC6A12 expression have been associated with Alzheimer's disease (AD), where it is identified as a hub gene with high expression levels in AD patients. This upregulation is linked to the immune response in AD, with certain immune cells showing positive or negative correlations with SLC6A12 expression (Zou2023Exploration).

In the context of liver and kidney function, SLC6A12 is involved in the uptake of betaine, which has therapeutic potential for conditions such as mild hyperhomocysteinemia, nonalcoholic steatohepatitis, and alcohol-induced liver damage. However, BGT1 knockout mice do not exhibit significant health issues under normal conditions, suggesting redundancy in betaine transport mechanisms (Zhou2012The).

The SLC6 family, to which SLC6A12 belongs, is associated with various neurological and psychiatric disorders, including depression, anxiety, and schizophrenia. While specific mutations in SLC6A12 have not been directly linked to these conditions, the gene's role in neurotransmitter transport suggests potential involvement in such disorders (Pramod2013SLC6). Further research is needed to fully understand the clinical implications of SLC6A12 in these diseases.


## References


[1. (Zou2023Exploration) Cuihua Zou, Li Su, Mika Pan, Liechun Chen, Hepeng Li, Chun Zou, Jieqiong Xie, Xiaohua Huang, Mengru Lu, and Donghua Zou. Exploration of novel biomarkers in alzheimer’s disease based on four diagnostic models. Frontiers in Aging Neuroscience, February 2023. URL: http://dx.doi.org/10.3389/fnagi.2023.1079433, doi:10.3389/fnagi.2023.1079433. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnagi.2023.1079433)

[2. (Zhou2012The) Y. Zhou, S. Holmseth, R. Hua, A. C. Lehre, A. M. Olofsson, I. Poblete-Naredo, S. A. Kempson, and N. C. Danbolt. The betaine-gaba transporter (bgt1, slc6a12) is predominantly expressed in the liver and at lower levels in the kidneys and at the brain surface. American Journal of Physiology-Renal Physiology, 302(3):F316–F328, February 2012. URL: http://dx.doi.org/10.1152/ajprenal.00464.2011, doi:10.1152/ajprenal.00464.2011. This article has 113 citations and is from a peer-reviewed journal.](https://doi.org/10.1152/ajprenal.00464.2011)

[3. (Colas2020Toward) Claire Colas. Toward a systematic structural and functional annotation of solute carriers transporters—example of the slc6 and slc7 families. Frontiers in Pharmacology, August 2020. URL: http://dx.doi.org/10.3389/fphar.2020.01229, doi:10.3389/fphar.2020.01229. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2020.01229)

[4. (Kickinger2021Molecular) Stefanie Kickinger, Maria E. K. Lie, Akihiro Suemasa, Anas Al-Khawaja, Koichi Fujiwara, Mizuki Watanabe, Kristine S. Wilhelmsen, Christina B. Falk-Petersen, Bente Frølund, Satoshi Shuto, Gerhard F. Ecker, and Petrine Wellendorph. Molecular determinants and pharmacological analysis for a class of competitive non-transported bicyclic inhibitors of the betaine/gaba transporter bgt1. Frontiers in Chemistry, September 2021. URL: http://dx.doi.org/10.3389/fchem.2021.736457, doi:10.3389/fchem.2021.736457. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fchem.2021.736457)

[5. (Lehre2011Deletion) A.C. Lehre, N.M. Rowley, Y. Zhou, S. Holmseth, C. Guo, T. Holen, R. Hua, P. Laake, A.M. Olofsson, I. Poblete-Naredo, D.A. Rusakov, K.K. Madsen, R.P. Clausen, A. Schousboe, H.S. White, and N.C. Danbolt. Deletion of the betaine–gaba transporter (bgt1; slc6a12) gene does not affect seizure thresholds of adult mice. Epilepsy Research, 95(1–2):70–81, June 2011. URL: http://dx.doi.org/10.1016/j.eplepsyres.2011.02.014, doi:10.1016/j.eplepsyres.2011.02.014. This article has 58 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.eplepsyres.2011.02.014)

[6. (Pramod2013SLC6) Akula Bala Pramod, James Foster, Lucia Carvelli, and L. Keith Henry. Slc6 transporters: structure, function, regulation, disease association and therapeutics. Molecular Aspects of Medicine, 34(2–3):197–219, April 2013. URL: http://dx.doi.org/10.1016/j.mam.2012.07.002, doi:10.1016/j.mam.2012.07.002. This article has 233 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2012.07.002)

[7. (Freissmuth2017SLC6) Michael Freissmuth, Thomas Stockner, and Sonja Sucic. SLC6 Transporter Folding Diseases and Pharmacochaperoning, pages 249–270. Springer International Publishing, 2017. URL: http://dx.doi.org/10.1007/164_2017_71, doi:10.1007/164_2017_71. This article has 29 citations.](https://doi.org/10.1007/164_2017_71)

[8. (Kempson2014The) Stephen A. Kempson, Yun Zhou, and Niels C. Danbolt. The betaine/gaba transporter and betaine: roles in brain, kidney, and liver. Frontiers in Physiology, April 2014. URL: http://dx.doi.org/10.3389/fphys.2014.00159, doi:10.3389/fphys.2014.00159. This article has 93 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphys.2014.00159)